Viking Global Investors

Type

Private equity

Status

Active

Location

Greenwich, United States

Total investments

171

Average round size

121M

Portfolio companies

104

Rounds per year

6.84

Lead investments

39

Follow on index

0.39

Exits

25

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
BiotechnologySoftwareInformation TechnologyHealth CareGeneticsMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

Viking Global Investors appeared to be the Corporate Investor, which was created in 1999. The main department of described Corporate Investor is located in the Greenwich. The venture was found in North America in United States.

The top amount of exits for fund were in 2019. Comparing to the other companies, this Viking Global Investors performs on 11 percentage points less the average number of lead investments. The fund is constantly included in 2-6 deals per year. When the investment is from Viking Global Investors the average startup value is more than 1 billion dollars. Deals in the range of more than 100 millions dollars are the general things for fund. The real fund results show that this Corporate Investor is 18 percentage points more often commits exit comparing to other companies. The top activity for fund was in 2019.

The overall number of key employees were 1.

Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Moderna Therapeutics, Roivant Sciences, Credit Karma. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in a number of founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little. Among the most successful fund investment fields, there are Agriculture, Genetics.

The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Viking Global Investors, startups are often financed by Illumina Accelerator, Felicis Ventures, Tenaya Capital. The meaningful sponsors for the fund in investment in the same round are Perceptive Advisors, Wellington Management, T. Rowe Price. In the next rounds fund is usually obtained by Y Combinator, Senator Investment Group, SVG Ventures.

Show more

Investor highlights

Industry focus
Biotech/Life SciencesHealthcareConsumer/RetailAnalyticsCybersecurity Show 7 more
Stage focus
Series ASeries B
Geo focus
Generalist

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
171
Lead investments
39
Exits
25
Rounds per year
6.84
Follow on index
0.39
Investments by industry
  • Biotechnology (103)
  • Health Care (54)
  • Therapeutics (32)
  • Medical (31)
  • Pharmaceutical (28)
  • Show 108 more
Investments by region
  • United States (145)
  • United Kingdom (5)
  • Canada (6)
  • China (2)
  • Mexico (2)
  • Show 5 more
Peak activity year
2021
Number of Unicorns
18
Number of Decacorns
18
Number of Minotaurs
9

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
9
Avg. valuation at time of investment
727M
Group Appearance index
0.95
Avg. company exit year
6
Avg. multiplicator
5.03
Strategy success index
1.00

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Astarte Medical 07 May 2019 Analytics, Health Care, Health Diagnostics, Medical, Predictive Analytics Early Stage Venture 5M United States, Pennsylvania
Diagonal Therapeutics 03 Apr 2024 Early Stage Venture 128M United States, Massachusetts, Cambridge

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.